



# FINANCIAL TEAR SHEET

## Corporate Profile

Apricus is committed to developing sexual health therapies in areas of high unmet needs. We have disciplined leadership focused on execution and are driving near-term shareholder value through regulatory approval, commercialization and partnering initiatives.

## Stock Performance

APRI (Common Stock)	
Exchange	NASDAQ (US Dollar)
Price	<b>\$0.37</b>
Change (%)	<b>▲ 0.04 (12.12%)</b>
Volume	5,911,979
52 Week High	\$3.34
52 Week Low	\$0.25
Market Cap	\$7,698,172
Rolling EPS	-0.71
PE Ratio	0
Shares Outstanding	23,441,449

Data as of 10/17/18 12:47 p.m. ET



## Recent Headlines

08/09/18  
[Apricus Biosciences Provides Corporate Update and Second Quarter 2018 Financial Results](#)

07/30/18  
[Apricus Biosciences, Inc. Announces Merger Agreement with Seelos Therapeutics, Inc. to Advance Late-Stage Pipeline of Products for Central Nervous System \(CNS\) Disorders](#)

05/03/18  
[Apricus Biosciences Provides Corporate Update and First Quarter 2018 Financial Results](#)

## Upcoming Events

There are currently no events scheduled.

## SEC Filings

Filing Date	Form
10/17/18	8-K
10/17/18	425
10/10/18	8-K
09/27/18	SC 13D

Data provided by Nasdaq. Minimum 15 minutes delayed. [View Attributions and Sources](#)

---

© Apricus Biosciences, Inc.